Clare London

This inventor holds 18 USPTO granted patents and 4 published patent applications, plus 1 CIPO patent and 13 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Merck Sharp + Dohme Corp., Elexopharm Gmbh, Merck Sharpe & Dohme Corp.. Active years: 2006-2020.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Clare London. Retrieved from https://idiyas.com/inventor/clare-london

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 18 (Patent Applications = 4)

% Patents Active = 83.3

CIPO Patents = 1

EPO Patents = 13 (Patent Applications = 15)

Average Co-Inventor Count = 8.4

ph-index = 3

Forward Citations = 27(Granted Patents)

Location History:

Sawbridgeworth, GB (2006)
Chatham, NJ (US) (2011 - 2020)

Company Filing History:

17 out of 2,405

Merck Sharp + Dohme Corp.

Merck Sharpe & Dohme Corp.

where one patent can have more than one assignee

Years Active: 2006-2020

Loading Chart...

Areas of Expertise:

Tetrahydroisoquinoline

Aldosterone Synthase

Diacylglyceride O-Acyltransferase 2

Calcium Channel Blockers

Viral Diseases

Spiropiperidinyl Compounds

Metallo-Beta-Lactamase

Sodium Channel Blockers

Heterocyclic Compounds

Triazolopyridyl

Oxindoline Derivatives

5-HT7 Receptor Ligands

18 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10568876 - Tetrahydroisoquinoline derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2 (2020-02-25),

2. 9877957 - Tetrahydroisoquinoline derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2 (2018-01-30),

3. 9844553 - Pyrazolopyridyl compounds as aldosterone synthase inhibitors (2017-12-19),

4. 9828369 - Isoquinoline derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2 (2017-11-28),

5. 9708336 - Metallo-beta-lactamase inhibitors (2017-07-18),

6. 9708270 - Substituted spiropiperidinyl compounds useful as GPR120 agonists (2017-07-18),

7. 9567333 - Triazolopyridyl compounds as aldosterone synthase inhibitors (2017-02-14),

8. 9549921 - Heterocyclic compounds and methods of use thereof for the treatment of hepatitis C (2017-01-24),

9. 9522141 - Indazole compounds as aldosterone synthase inhibitors (2016-12-20),

10. 9518055 - Imidazopyridyl compounds as aldosterone synthase inhibitors (2016-12-13),

11. 9382226 - Aldosterone synthase inhibitors (2016-07-05),

12. 9351973 - Pyrazolopyridyl compounds as aldosterone synthase inhibitors (2016-05-31),

13. 9265773 - Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases (2016-02-23),

14. 9193724 - Triazolopyridyl compounds as aldosterone synthase inhibitors (2015-11-24),

15. 9073929 - Aldosterone synthase inhibitors (2015-07-07),

Title: Innovator Clare London: Pioneering Advances in Pharmaceutical Chemistry

Introduction

Clare London, an accomplished inventor based in Chatham, NJ (US), has made remarkable contributions to the field of pharmaceutical chemistry. With a portfolio of 18 patents, Clare is recognized for her innovative work in the development of compounds that may offer new treatment avenues for various diseases.

Latest Patents

Among her most notable inventions are her recent patents involving tetrahydroisoquinoline derivatives, which are identified as potential inhibitors of diacylglyceride O-acyltransferase 2 (DGAT2). These compounds are represented by a specific formula and include pharmaceutically acceptable salts. The significance of these compounds lies in their potential application in the treatment, prevention, and suppression of diseases influenced by DGAT2. Such diseases include hepatic steatosis, diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, and various cardio-renal ailments, including chronic kidney disease and heart failure.

Career Highlights

Clare has demonstrated a strong commitment to her field through her work with several prominent companies. Notably, she has been associated with Merck Sharp & Dohme Corporation and Elexopharm GmbH, where she has contributed to significant advancements in pharmaceutical research and development. Her breadth of experience has established her as a key figure in innovation within the industry.

Collaborations

Throughout her career, Clare has had the opportunity to work alongside esteemed colleagues such as Yusheng Xiong and Scott B. Hoyt. These collaborations have helped foster an environment of creativity and collective innovation, leading to breakthroughs that address pressing health concerns.

Conclusion

Clare London exemplifies the spirit of innovation, contributing to critical advances in medical science through her research and patent achievements. With her continued dedication, the future looks promising as her inventions could pave the way for new therapies that benefit countless individuals confronting health challenges.

Profile summary based on public USPTO records.